Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
25-NSE
Exchange delisting
21 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
S-3
Shelf registration
24 Jan 24
S-8
Registration of securities for employees
24 Jan 24
8-K
Entry into a Material Definitive Agreement
9 Jan 24
8-K
Departure of Directors or Certain Officers
28 Dec 23
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Oct 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
424B5
Prospectus supplement for primary offering
20 Sep 23
8-K
Other Events
18 Sep 23
8-K
Departure of Directors or Certain Officers
15 Sep 23
8-K
Other Events
7 Sep 23
8-K
Departure of Directors or Certain Officers
29 Aug 23
8-K
Regulation FD Disclosure
21 Aug 23
8-K
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
14 Aug 23
424B5
Prospectus supplement for primary offering
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Other Events
3 Aug 23
8-K
Other Events
13 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
8-K
Other Events
15 Jun 23
8-K
Other Events
6 Jun 23
424B5
Prospectus supplement for primary offering
24 May 23
8-K
Entry into a Material Definitive Agreement
24 May 23
8-K
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
15 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
CT ORDER
Confidential treatment order
24 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Apr 23
8-K
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
3 Apr 23
S-8
Registration of securities for employees
31 Mar 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Entry into a Material Definitive Agreement
9 Mar 23
8-K
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
1 Dec 22
Latest ownership filings
4
Alan Edmund Walts
26 Jan 24
4
Steven D Rubin
26 Jan 24
4
Lindsay Androski
26 Jan 24
4
Sumit Aggarwal
26 Jan 24
SC 13G/A
ROCHE FINANCE LTD
13 Feb 23
4
Alan Edmund Walts
31 Jan 23
4
Steven D Rubin
31 Jan 23
4
Tomer Kariv
31 Jan 23
4
Lindsay Androski
31 Jan 23
4
Sumit Aggarwal
27 Jan 23
4
VIJAY MODUR
27 Jan 23
4
Lindsay Androski
6 Jul 22
3
Lindsay Androski
6 Jul 22
4
Alan Edmund Walts
17 Jun 22
4
Gadi Veinrib
17 Jun 22
4
Jasbir Seehra
17 Jun 22
4
Steven D Rubin
17 Jun 22
4
RAJESH B PAREKH
17 Jun 22
4
Ran Nussbaum
17 Jun 22
4
Tomer Kariv
17 Jun 22
4
Zafrira Avnur
17 Jun 22
SC 13G/A
ROCHE FINANCE LTD
14 Feb 22
SC 13D/A
LSP V Cooperatieve U.A.
3 Feb 22
4
Alan Edmund Walts
3 Dec 21
4
Sumit Aggarwal
3 Dec 21
4
VIJAY MODUR
3 Dec 21
4
Daniel E. Geffken
1 Dec 21
4
Neil S. Belloff
30 Jul 21
SC 13G
Gurnet Point L.P.
29 Jun 21
SC 13G
ROCHE FINANCE LTD
14 Jun 21
4
Neil S. Belloff
26 May 21
SC 13D/A
Pontifax Management III G.P. (2011) Ltd.
21 May 21
4
Alan Edmund Walts
20 May 21
4
RAJESH B PAREKH
20 May 21
4
Zafrira Avnur
20 May 21
4
Ran Nussbaum
20 May 21
4
Tomer Kariv
20 May 21
4
Gadi Veinrib
20 May 21
4
Steven D Rubin
20 May 21
4
Jasbir Seehra
20 May 21